HIV感染者中富马酸替诺福韦酯抗HBV的功效

作     者：Benhamou Y Fleury H. Trimoulet P. 陈云茹(译) 史敏(校) 

作者机构：Service d' Hépato-Gastroentérologie Hopital Pitié Salpetri' ere 27 Boulevard de I'Hopital 75013 ParisFrance 不详 

出 版 物：《世界核心医学期刊文摘（胃肠病学分册）》 (Core Journals in Gastroenterology)

年 卷 期：2006年第2卷第9期

页      面：49-49页

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：HIV感染者 抗HBV 替诺福韦酯 富马酸 抗逆转录病毒治疗 HBeAg阴性 功效 乙肝病毒e抗原 

摘      要：Tenofovir disoproxil fumarate(TDF)has shown in vitro activity against both HIV and hepatitis B virus(HBV).We retrospectively evaluated the efficacy of TDF(300 mg/d),administered as a part of anti-retroviral therapy,in a large cohort of HIV/HBVcoinfected ***-five HIV/HBV-coinfected patients who received TDF for at least 6 months with serum HBV DNA levels above 2.3 log10 copies/mL at TDF initiation and who had stored serum samples before and during TDF therapy were *** HBV DNA was measured on stored *** median follow-up period was 12(Q1-Q3:8-17)*** hepatitis B e antigen(HBeAg)was positive in 54 patients(83.1%).Fifty-two patients(80.0%)were receiving lamivudine(LAM)(150 mg twice a day),and 68.8%had documented LAM resistance at *** HBeAg positive patients,the median reduction from baseline(8.17;Q1-Q3 = 7.30-8.30 log10copies/mL)of serum HBV DNA was 4.56 log10 copies/mL(Q1-Q3 = 3.33-5.55)(P .0001).In HBeAg-negative patients,serum HBV DNA decline from baseline(4.83;Q1-Q3 = 2.69-6.40 log10 copies/mL)was 2.53 log10 copies/mL(Q1-Q3 = 0.39-4.10).At the end of the study,HBV DNA became undetectable in 29.6%and 81.6%of the HBeAg positive and HBeAg-negative patients,*** HBeAg became negative in 4 patients,2 of whom acquired serum hepatitis B e *** conclusion,this retrospective analysis demonstrates the efficacy of TDF against wild-type,presumed precore mutants and LAM-resistant HBV when used as a part of anti-retroviral therapy in HIV-coinfected patients.